{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:36:06Z","timestamp":1794072966943,"version":"4.8.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"15","license":[{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,13]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>A2 domain dissociation in activated factor VIII (FVIIIa) results in reduced activity. Previous studies demonstrated that some FVIII mutants (D519V\/E665V and K1813A) with delayed A2 dissociation enhanced coagulation potential. We speculated, therefore, that FVIII encompassing a combination of these mutations might further enhance coagulant activity. The aim was to assess the D519V\/E665V\/K1813A-FVIII mutation as a gain of function. The FVIII mutants, D519V\/E665V\/K1813A, D519V\/E665V, and K1813A were expressed in a baby hamster kidney cell system, and global coagulation potential of these mutants was compared with wild-type (WT) FVIII in\u00a0vitro and in hemophilia A mice in\u00a0vivo. Kinetic analyses indicated that the apparent Kd for FIXa on the tenase assembly with D519V\/E665V and D519V\/E665V\/K1813A mutants were lower, and that the generated FXa for D519V\/E665V\/K1813A was significantly greater than WT-FVIII. WT-FVIII activity after thrombin activation increased by \u223c12-fold within 5\u00a0minutes, and returned to initial levels within 30\u00a0minutes. In contrast, The FVIII-related activity of D519V\/E665V\/K1813A increased further with time after thrombin activation, and showed an \u223c25-fold increase at 2 hours. The A2 dissociation rate of D519V\/E665V\/K1813A was \u223c50-fold slower than the WT in a 1-stage clotting assay. Thrombin generation assays demonstrated that D519V\/E665V\/K1813A (0.125 nM) exhibited coagulation potential comparable with that of the WT (1 nM). In animal studies, rotational thromboelastometry and tail-clip assays showed that the coagulation potential of D519V\/E665V\/K1813A (0.25\u00a0\u03bcg\/kg) was equal to that of the WT (2\u00a0\u03bcg\/kg). FVIII-D519V\/E665V\/K1813A mutant could provide an approximately eightfold increase in hemostatic function of WT-FVIII because of increased FVIIIa stability and the association between FVIIIa and FIXa.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012391","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T19:37:10Z","timestamp":1717184230000},"page":"3929-3940","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["The combination of Asp519Val\/Glu665Val and Lys1813Ala mutations in FVIII markedly increases coagulation potential"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5422-2782","authenticated-orcid":false,"given":"Yuto","family":"Nakajima","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, Nara Medical University, Kashihara, Japan"},{"name":"2Advanced Medical Science of Thrombosis and Hemostasis, Nara Medical University, Kashihara City, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0819-2388","authenticated-orcid":false,"given":"Akihisa","family":"Oda","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, Nara Medical University, Kashihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3004-8457","authenticated-orcid":false,"given":"Nemekhbayar","family":"Baatartsogt","sequence":"additional","affiliation":[{"name":"3Department of Biochemistry, Jichi Medical University School of Medicine, Shimotsuke, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0585-3937","authenticated-orcid":false,"given":"Yuji","family":"Kashiwakura","sequence":"additional","affiliation":[{"name":"3Department of Biochemistry, Jichi Medical University School of Medicine, Shimotsuke, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5082-6394","authenticated-orcid":false,"given":"Tsukasa","family":"Ohmori","sequence":"additional","affiliation":[{"name":"3Department of Biochemistry, Jichi Medical University School of Medicine, Shimotsuke, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, Nara Medical University, Kashihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"issue":"1","key":"2024081312405416000_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V76.1.1.1","article-title":"Surface-dependent reactions of the vitamin K-dependent enzyme complexes","volume":"76","author":"Mann","year":"1990","journal-title":"Blood"},{"issue":"5992","key":"2024081312405416000_bib2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/312330a0","article-title":"Expression of active human factor VIII from recombinant DNA clones","volume":"312","author":"Wood","year":"1984","journal-title":"Nature"},{"issue":"5992","key":"2024081312405416000_bib3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/312337a0","article-title":"Structure of human factor VIII","volume":"312","author":"Vehar","year":"1984","journal-title":"Nature"},{"issue":"3","key":"2024081312405416000_bib4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0167-4838(86)90208-6","article-title":"The size of human factor VIII heterodimers and the effects produced by thrombin","volume":"871","author":"Fay","year":"1986","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"2024081312405416000_bib5","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1021\/bi00350a035","article-title":"Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity","volume":"25","author":"Eaton","year":"1986","journal-title":"Biochemistry"},{"issue":"24","key":"2024081312405416000_bib6","doi-asserted-by":"crossref","first-page":"17006","DOI":"10.1016\/S0021-9258(18)41885-6","article-title":"Binding of factor VIIIa and factor VIII to factor IXa on phospholipid vesicles","volume":"267","author":"Duffy","year":"1992","journal-title":"J\u00a0Biol Chem"},{"issue":"19","key":"2024081312405416000_bib7","doi-asserted-by":"crossref","first-page":"11120","DOI":"10.1074\/jbc.271.19.11120","article-title":"Activation of the factor VIIIa-factor IXa enzyme complex of blood coagulation by membranes containing phosphatidyl-L-serine","volume":"271","author":"Gilbert","year":"1996","journal-title":"J\u00a0Biol Chem"},{"issue":"24","key":"2024081312405416000_bib8","doi-asserted-by":"crossref","first-page":"16355","DOI":"10.1074\/jbc.M708985200","article-title":"Detailed mechanisms of the inactivation of factor VIIIa by activated protein C in the presence of its cofactors, protein S and factor V","volume":"283","author":"Gale","year":"2008","journal-title":"J\u00a0Biol Chem"},{"issue":"7","key":"2024081312405416000_bib9","first-page":"501","article-title":"Activated protein C resistance--a major risk factor for thrombosis","volume":"35","author":"Ros\u00e9n","year":"1997","journal-title":"Eur J Clin Chem Clin Biochem"},{"issue":"3","key":"2024081312405416000_bib10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1538-7836.2009.03711.x","article-title":"APC resistance: biological basis and acquired influences","volume":"8","author":"Castoldi","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"2024081312405416000_bib11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1042\/BJ20060117","article-title":"Role of P1 residues Arg336 and Arg562 in the activated-Protein-C-catalysed inactivation of factor VIIIa","volume":"396","author":"Varfaj","year":"2006","journal-title":"Biochem J"},{"issue":"19","key":"2024081312405416000_bib12","doi-asserted-by":"crossref","first-page":"12481","DOI":"10.1016\/S0021-9258(18)98924-6","article-title":"Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog","volume":"266","author":"Lollar","year":"1991","journal-title":"J\u00a0Biol Chem"},{"issue":"6","key":"2024081312405416000_bib13","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1182\/blood.V63.6.1303.1303","article-title":"Stabilization of thrombin-activated porcine factor VIII:C by factor IXa phospholipid","volume":"63","author":"Lollar","year":"1984","journal-title":"Blood"},{"issue":"18","key":"2024081312405416000_bib14","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1182\/blood.2020007562","article-title":"Activated protein C has a regulatory role in factor VIII function","volume":"137","author":"Wilhelm","year":"2021","journal-title":"Blood"},{"issue":"14","key":"2024081312405416000_bib15","doi-asserted-by":"crossref","first-page":"8957","DOI":"10.1016\/S0021-9258(18)31537-0","article-title":"Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1\/A3-C1-C2 dimer and A2 subunit","volume":"266","author":"Fay","year":"1991","journal-title":"J\u00a0Biol Chem"},{"issue":"7","key":"2024081312405416000_bib16","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1182\/blood-2008-02-142158","article-title":"Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface","volume":"112","author":"Wakabayashi","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2024081312405416000_bib17","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood-2014-02-555656","article-title":"Noncovalent stabilization of the factor VIII A2 domain enhances efficacy in hemophilia A mouse vascular injury models","volume":"125","author":"Leong","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2024081312405416000_bib18","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1182\/bloodadvances.2022008187","article-title":"Factor VIII mutated with Lys1813Ala within the factor IXa-binding region enhances intrinsic coagulation potential","volume":"7","author":"Nakajima","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2024081312405416000_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2257.2004.00605.x","article-title":"Usefulness of synthetic phospholipid in measurement of activated partial thromboplastin time: a new preparation procedure to reduce batch difference","volume":"26","author":"Okuda","year":"2004","journal-title":"Clin Lab Haematol"},{"issue":"3","key":"2024081312405416000_bib20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/jth.15201","article-title":"The C-terminal acidic region in the A1 domain of factor VIII facilitates thrombin-catalyzed activation and cleavage at Arg372","volume":"19","author":"Nakajima","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"11","key":"2024081312405416000_bib21","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1182\/blood-2004-10-3939","article-title":"Thrombin-catalyzed activation of factor VIII with His substituted for Arg372 at the P1 site","volume":"105","author":"Nogami","year":"2005","journal-title":"Blood"},{"issue":"20","key":"2024081312405416000_bib22","doi-asserted-by":"crossref","first-page":"14020","DOI":"10.1074\/jbc.M114.550566","article-title":"Cofactor activity in factor VIIIa of the blood clotting pathway is stabilized by an interdomain bond between His281 and Ser524 formed in factor VIII","volume":"289","author":"Wakabayashi","year":"2014","journal-title":"J\u00a0Biol Chem"},{"issue":"10","key":"2024081312405416000_bib23","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1055\/s-0041-1723996","article-title":"Acidic region residues 1680-1684 in the A3 domain of factor VIII contain a thrombin-interactive site responsible for proteolytic cleavage at Arg1689","volume":"121","author":"Nakajima","year":"2021","journal-title":"Thromb Haemost"},{"issue":"7873","key":"2024081312405416000_bib24","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"issue":"11","key":"2024081312405416000_bib25","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41594-022-00849-w","article-title":"A\u00a0structural biology community assessment of AlphaFold2 applications","volume":"29","author":"Akdel","year":"2022","journal-title":"Nat Struct Mol Biol"},{"issue":"6","key":"2024081312405416000_bib26","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41592-022-01488-1","article-title":"ColabFold: making protein folding accessible to all","volume":"19","author":"Mirdita","year":"2022","journal-title":"Nat Methods"},{"issue":"1","key":"2024081312405416000_bib27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/jth.14621","article-title":"The 3.2\u00a0\u00c5 structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain","volume":"18","author":"Smith","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"2024081312405416000_bib28","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/prot.20264","article-title":"Scoring function for automated assessment of protein structure template quality","volume":"57","author":"Zhang","year":"2004","journal-title":"Proteins"},{"issue":"12","key":"2024081312405416000_bib29","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.3390\/biom12121764","article-title":"Boosting the full potential of PyMOL with structural biology plugins","volume":"12","author":"Rosignoli","year":"2022","journal-title":"Biomolecules"},{"issue":"1","key":"2024081312405416000_bib30","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/pro.3280","article-title":"Improvements to the APBS biomolecular solvation software suite","volume":"27","author":"Jurrus","year":"2018","journal-title":"Protein Sci"},{"issue":"1","key":"2024081312405416000_bib31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1160\/TH13-10-0918","article-title":"Combining mutations that modulate inter-subunit interactions and proteolytic inactivation enhance the stability of factor VIIIa","volume":"112","author":"Wakabayashi","year":"2014","journal-title":"Thromb Haemost"},{"issue":"2","key":"2024081312405416000_bib32","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1160\/TH13-02-0154","article-title":"Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in\u00a0vitro and in\u00a0vivo","volume":"110","author":"Kao","year":"2013","journal-title":"Thromb Haemost"},{"issue":"6","key":"2024081312405416000_bib33","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/bja\/aep098","article-title":"Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in\u00a0vitro model","volume":"102","author":"Bolliger","year":"2009","journal-title":"Br J Anaesth"},{"issue":"1","key":"2024081312405416000_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2019000007","article-title":"Gene therapy for hemophilia","volume":"2019","author":"Nathwani","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"11","key":"2024081312405416000_bib35","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jfma.2023.05.008","article-title":"Gene therapy for hemophilia, a clinical viewpoint","volume":"122","author":"Chou","year":"2023","journal-title":"J\u00a0Formos Med Assoc"},{"issue":"8","key":"2024081312405416000_bib36","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"2024081312405416000_bib37","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2024081312405416000_bib38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/hum.2014.106","article-title":"Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial","volume":"26","author":"Monahan","year":"2015","journal-title":"Hum Gene Ther"},{"issue":"suppl 1","key":"2024081312405416000_bib39","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood-2022-170646","article-title":"Inhibiting activated protein C cleavage of factor VIII for hemophilia a gene therapy","volume":"140","author":"Sternberg","year":"2022","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/15\/3929\/2237949\/blooda_adv-2023-012391-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/15\/3929\/2237949\/blooda_adv-2023-012391-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T12:41:21Z","timestamp":1723552881000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/15\/3929\/516339\/The-combination-of-Asp519Val-Glu665Val-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,25]]},"references-count":39,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,8,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012391","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,25]]}}}